Soliqua 100/33 (insulin glargine/lixisenatide) is a prescription drug that’s used to treat type 2 diabetes. Soliqua 100/33 comes as a prefilled single-use pen for injecting the drug under your skin.

Type 2 diabetes is the most common type of diabetes. It occurs when your blood has high levels of sugar, also known as glucose. This can cause your pancreas, which is the organ that produces insulin, ...

If you have type 2 diabetes, your doctor might suggest Soliqua 100/33 (insulin glargine and lixisenatide) as a treatment option for you. Knowing the possible side effects of this drug can help you and ...

Soliqua 100/33 is a brand-name prescription medication. It’s used with diet and exercise to improve blood sugar levels in adults with type 2 diabetes. Soliqua 100/33 contains two drugs: insulin ...

PARIS, June 28, 2021 /PRNewswire/ -- A new study of Soliqua ® 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL, iGlarLixi, met its two primary endpoints and all key ...

Years ago, Sanofi's Soliqua hit the diabetes market with the promise of combining an insulin and a GLP-1 medicine in a convenient once-daily treatment option for Type 2 diabetes. So far, though, sales ...

After 30 weeks, least squares (LS) mean reductions in HbA1c for the Soliqua 100/33 treatment groups were 1.09%, 1.44% and 2.41%, respectively. After 30 weeks of treatment, Soliqua 100/33 (insulin ...

PARIS - June 9, 2019 - In a Phase 3 study [1] evaluating adults with type 2 diabetes inadequately controlled by GLP-1 receptor agonist (GLP-1 RA) treatments, Soliqua ® /Suliqua ®[2] (insulin glargine ...

Sanofi announced the launch of Soliqua 100/33 (insulin glargine and lixisenatide injection) for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin ( Sanofi announced ...

Sanofi has launched new diabetes combination therapy Soliqua in the US ahead of a rival product from Novo Nordisk. Soliqua (insulin glargine/lixisenatide) reaches the market ahead of Novo Nordisk’s ...